A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment
Completed
- Conditions
- Mild Cognitive Impairment
- Interventions
- Other: SAMSTAROther: RAVLT
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 153
- Registration Number
- NCT02419183
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Phase 3
Completed
- Conditions
- Treatment-resistant Depression
- Interventions
- Drug: PlaceboDrug: EsketamineDrug: Duloxetine (Oral Antidepressant)Drug: Escitalopram (Oral antidepressant)Drug: Sertraline (Oral Antidepressant)Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 236
- Registration Number
- NCT02418585
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Phase 3
Completed
- Conditions
- Treatment-resistant Depression
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 346
- Registration Number
- NCT02417064
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Phase 2
Terminated
- Conditions
- Lymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02413489
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- Colitis, UlcerativeInflammatory Bowel Diseases
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 961
- Registration Number
- NCT02407236
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
Phase 3
Terminated
- Conditions
- Nonradiographic Axial Spondylitis, Ankylosing
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 356
- Registration Number
- NCT02407223
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- Drug: JNJ-54861911, 10 mgDrug: JNJ-54861911, 25 mgDrug: PlaceboDrug: JNJ-54861911, 5 mg
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT02406027
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02397382
A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02390609
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Phase 1
Completed
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02381080
© Copyright 2025. All Rights Reserved by MedPath